borderline significantp = 0.14
Patients with higher score of the immune response module IMMUNE1 showed no significant tamoxifen benefit (HR (95% CI) = 0.67 (0.34–1.33)), whereas patients with low IMMUNE1 score did (HR (95% CI) = 0.35 (0.20–0.61)) with borderline significant interaction test in univariate ( p = 0.14) and multivariable analyses ( p = 0.09) ( Figure 6 E,F).